Enhancement of muscle gene delivery with pseudotyped adeno-associated virus type 5 correlates with myoblast differentiation

Journal of Virology

Volumn 75, Issue 16, 2001, Pages 7662-7671

  Duan, D ^a   Yan, Z ^a   Yue, Y ^a   Ding, W ^a   Engelhardt, J F ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; MOUSE; MUSCLE CELL; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE; TRANSGENE; VIRUS RECOMBINANT; VIRUS TYPING;

ANIMALS; CELL DIFFERENTIATION; CELL LINE; DEPENDOVIRUS; GENE THERAPY; GENETIC VECTORS; HUMANS; MUSCLE, SKELETAL; TRANSFECTION;

EID: 0034907414     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.16.7662-7671.2001     Document Type: Article

References (40)

1. Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses
2. X chromosome-linked muscular dystrophy (mdx) in the mouse
3. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors
4. Cloning and characterization of adeno-associated virus type 5
5. Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles
6. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies
7. Rescue of skeletal muscles of r-sarcoglycan deficient mice with adeno-associated virus-mediated gene transfer
8. Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system
9. Structural and functional heterogeneity of integrated recombinant AAV genomes
10. Dynamin is required for recombinant adeno-associated virus type 2 infection
11. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long term episomal persistence in muscle
12. A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation
13. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus
14. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2
15. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector
16. Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter
17. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
18. rAAV vector-mediated sarcoglycan gene transfer in a hamster model for limb girdle muscular dystrophy
19. Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3
20. Retargeting the coxsackievirus and adenovirus receptor to the apical surface of polarized epithelial cells reveals the glycocalyx as a barrier to adenovirus-mediated gene transfer
21. The use of adeno-associated virus to circumvent the maturation-dependent viral transduction of muscle fibers
22. Adeno-associated virus type 2-mediated gene transfer: Correlation of tyrosine phosphorylation of the cellular single-stranded D sequence-binding protein with transgene expression in human cells in vitro and murine tissues in vivo
23. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2
24. Helper-free stocks of recombinant adeno-associated viruses: Normal integration does not require viral gene expression
25. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication
26. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions
27. Transient promoter activity in primary rat mammary epithelial cells evaluated using particle bombardment gene transfer
28. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors
29. A tumultuous year for gene therapy
30. Cell cycle exit upon myogenic differentiation
31. Incorporation of adeno-associated virus in a calcium phosphate coprecipitate improves gene transfer to airway epithelia in vitro and in vivo
32. Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer
33. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model
34. Reversible denaturation of Aequorea green-fluorescent protein: Physical separation and characterization of the renatured protein
35. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism
36. Gene therapy vectors based on adeno-associated virus type 1
37. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus
38. A myogenic cell line with altered serum requirements for differentiation
39. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy
40. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer